StemRIM Earnings beat, Revenue Inline In Q4
- Investing.com
Metrics to compare | 4599 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4599PeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.1x | −5.4x | −0.2x | |
PEG Ratio | −0.84 | −0.21 | 0.00 | |
Price/Book | 1.3x | 3.0x | 2.6x | |
Price / LTM Sales | - | 12.9x | 2.7x | |
Upside (Analyst Target) | - | 139.5% | 68.5% | |
Fair Value Upside | Unlock | 19.4% | 11.5% | Unlock |
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, acute ischemic stroke, cerebral infarction, myocardial infarction/cardiomyopathy, chronic liver disease, and knee osteoarthritis. It also develops TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a gene therapy for the treatment of epidermolysis bullosa. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.